| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
electroCore, Inc.$8.92
+0.25 (+2.87%)
F 17Pipeline Score MedTech · Commercial
Market Cap
55.33 M
EPS
-1.81
P/E Ratio
-
Value Trade
1.29 M
SEC Financials
Q1 2026Dilution Risk
Revenue
9.58 M
Operating CF
-3.01 M
Total Assets
15.48 M
Total Liabilities
21.17 M
Equity
-5.69 M
D/E Ratio
12,345
6.38 %
Week
7.41 %
1 Month
10.61 %
3 Month
44.37 %
6 Month
-72.38 %
5 Year
-97.53 %
All Time
Cash Data
Cash Position
8.83 M
Monthly Burn
1.00 M
Runway
7.7 mo
Burn Trend
SEC Filing
May 6, 2026
Overview
Volume
8.25 K
52 Week Range
4.16 - 8.64
% held by Insiders
38.24 %
% held by Institutions
11.36 %
Enterprise Value
55.99 M
Total Shares
8.08 M
Short %
5.48 %
Float Shares
4.90 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
F17
Pipeline Score $0M
Pipeline ValueValuation Signal
1
Drugs Scored0.0x
rNPV / MCap Top 16%
Micro Cap (rank 761 of 905)
Percentile RankelectroCore, Inc. has significant pipeline risk (17/100), with $15M risk-adjusted pipeline value, led by GammaCore in Chronic Cluster Headache (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GammaCore Unknown | Chronic Cluster Headache | Phase 2 | NCT01701245 | 16% | $15M | COMPLETED | 97 | - | - | Oct 1, 2014 | - | Apr 25, 2016 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ECOR
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
electroCore, Inc. (ECOR) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
ECOR
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ECOR
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ECOR
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ECOR Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
ECOR Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ECORelectroCore to Participate in iAccess Alpha Virtual Best Ideas Summer Investment Conference
electroCore, Inc. will participate in the iAccess Alpha Virtual Best Ideas Summer Investment Conference on June 23-24, 2026. The company's Interim President and CFO, Joshua Lev, will present and conduct one-on-one meetings with investors. This event highlights electroCore's commitment to engaging with investors and promoting its bioelectronic health technologies.
Read more →ECORFrontiers in Neuroscience Accepts Review Article Synthesizing Evidence that Cervical nVNS Activates the Vagus Nerve Without Surgery
electroCore, Inc. announced that a review article on cervical non-invasive vagus nerve stimulation (nVNS) has been accepted for publication in Frontiers in Neuroscience. Authored by a team of experts, the article consolidates evidence supporting the effectiveness of nVNS in activating vagal pathways without surgery. This publication aims to address skepticism regarding non-invasive vagal activation and reinforces the clinical validation of cervical nVNS.
Read more →ECORelectroCore to Present at the Planet MicroCap Las Vegas 2026 Powered by MicroCapClub
electroCore, Inc. will present at the Planet MicroCap Las Vegas 2026 event, scheduled for June 17-18, 2026. Interim President and CFO Joshua Lev will lead the presentation and conduct one-on-one investor meetings. The event aims to connect public companies with investors, highlighting electroCore's advancements in bioelectronic medicine.
Read more →ECORelectroCore Announces Publication in JAMA Highlighting the Benefits of Adding Quell Electrical Nerve Stimulation to Outpatient Physical Therapy in Fibromyalgia
electroCore, Inc. announced the publication of a study in JAMA Network Open, demonstrating the effectiveness of the Quell device in reducing pain for fibromyalgia patients undergoing outpatient physical therapy. The study involved 384 participants and showed significant improvements in pain and fatigue levels. The results indicate that Quell may serve as a beneficial non-drug treatment option for fibromyalgia.
Read more →ECORelectroCore to Present at the LD Micro Invitational XVI Conference on May 18, 2026
electroCore, Inc. will present at the LD Micro Invitational XVI Conference on May 18, 2026. The event will take place at the Luxe Sunset Boulevard hotel in Los Angeles, where Interim President and CFO Joshua Lev will deliver a presentation and conduct one-on-one meetings. This engagement highlights the company's focus on bioelectronic medicine and wellness.
Read more →ECORelectroCore TAC-STIM™ Named National Semifinalist in National Safety Council Work to Zero Challenge
electroCore, Inc. announced that its TAC-STIM product has been named a national semifinalist in the 2026 Work to Zero Safety Innovation Challenge. This initiative by the National Safety Council aims to identify technologies that can mitigate workplace fatigue, a significant safety risk. TAC-STIM is designed to enhance decision-making and performance in high-demand environments, particularly for military personnel.
Read more →ECORelectroCore to Announce First Quarter March 31, 2026, Financial Results on Wednesday, May 6, 2026
electroCore, Inc. will report its financial results for Q1 2026 on May 6, 2026. A webinar will be held at 4:30 PM EDT for management to discuss the results and answer investor questions. The company specializes in bioelectronic medicine, focusing on non-invasive technologies for chronic pain and wellness.
Read more →ECORelectroCore to Present at the Market Movers Investor Summit on May 5, 2026
electroCore, Inc. will present at the Market Movers Investor Summit on May 5, 2026, in New York City. Interim President and CFO Joshua Lev will lead the presentation and engage in one-on-one meetings. The summit aims to connect company executives with investors, featuring various programming elements including keynote sessions and networking opportunities.
Read more →ECORelectroCore Product Line Featured in Documentary Underscoring the Expanding Clinical and Commercial Role of Vagus Nerve Stimulation
electroCore, Inc. announced its participation in the documentary 'Hacking the Vagus Nerve,' which explores the vagus nerve's role in health. The film features electroCore's technologies, including gammaCore for migraines and Truvaga Plus for stress management. As interest in vagus nerve stimulation grows, electroCore aims to advance its therapeutic applications.
Read more →ECORelectroCore to Participate in the 25th Annual Needham Virtual Healthcare Conference
electroCore, Inc. will participate in the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026. Interim President Joshua Lev will present at 2:15 pm ET and engage in one-on-one meetings with investors. This event highlights the company's focus on advancing bioelectronic technologies for health improvement.
Read more →ECORelectroCore Announces First Patient Enrollment in Investigator-Led Study of gammaCore™ nVNS for PTSD
electroCore, Inc. has announced the enrollment of the first eight patients in a clinical study evaluating the safety and effectiveness of its gammaCore non-invasive vagus nerve stimulation device for PTSD. The study, conducted by Acacia Clinics and the Vagus Nerve Society, aims to enroll up to 40 participants over a 12-week period. Key endpoints include assessing treatment-related adverse events and changes in PTSD symptom scores.
Read more →ECORelectroCore Announces Publication in Frontiers in Neuroscience Highlighting Benefits of Non-Invasive Vagus Nerve Stimulation in Patients with Mild Traumatic Brain Injury and PTSD
electroCore, Inc. announced the publication of a study in Frontiers in Neuroscience, demonstrating the benefits of adjunctive non-invasive vagus nerve stimulation (nVNS) in patients with chronic mild traumatic brain injury (mTBI) and post-traumatic stress disorder (PTSD). The post-hoc analysis of 35 patients showed significant reductions in symptom burden across cognitive, affective, and somatic domains. This research adds to the existing literature on the therapeutic potential of nVNS.
Read more →ECORelectroCore Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
electroCore, Inc. has announced the hiring of Seth Abrams as VP of Sales and Michael Fox as COO, effective April 1 and April 13, 2026, respectively. Both executives will receive restricted stock units as part of their compensation, aligning with NASDAQ Listing Rule 5635(c)(4). The company aims to improve health through innovative bioelectronic technologies.
Read more →ECORelectroCore Expands Intellectual Property Portfolio
electroCore, Inc. announced the issuance of two new U.S. patents, enhancing its intellectual property portfolio in non-invasive vagus nerve stimulation technology. The patents cover innovative methods for vagus nerve modulation and remote patient monitoring. This expansion underscores electroCore's commitment to innovation and positions it strongly in the market for next-generation therapies.
Read more →ECORelectroCore to Announce Fourth Quarter and Full Year Ended December 31, 2025, Financial Results on Thursday, March 19, 2026
electroCore, Inc. has announced that it will report its financial results for the fourth quarter and full year ended December 31, 2025, on March 19, 2026. A webinar will be held at 4:30 PM EDT for management to review the results and answer investor questions. The company focuses on bioelectronic technologies aimed at improving health and quality of life.
Read more →ECORAcacia Clinics and Vagus Nerve Society Conduct Study Using electroCore’s gammaCore Sapphire for Adjunctive Treatment of Symptoms Associated with Post-Traumatic Stress Disorder (“PTSD”)
electroCore, Inc. announced a new research initiative in collaboration with Acacia Clinics and the Vagus Nerve Society to study the effectiveness of gammaCore Sapphire for treating PTSD symptoms. The study aims to assess safety and efficacy over a 12-week period, enrolling up to 40 participants. This initiative highlights the potential of non-invasive vagus nerve stimulation as a treatment option.
Read more →ECORelectroCore Provides Preliminary Full-Year 2025 Business Update; Expects ~26% Revenue Growth to ~$31.8–$32.0 Million
electroCore, Inc. has provided preliminary financial guidance indicating a projected revenue of $31.8 to $32.0 million for the full year 2025, representing a 26% increase from 2024. The fourth quarter is expected to show a 30% growth compared to the same quarter in 2024. However, the company’s cash position has decreased, raising concerns about future financial stability.
Read more →ECORTAC-STIM Demonstrates Significant Performance Improvements in Active-Duty United States Air Force Airmen
electroCore, Inc. announced a peer-reviewed study demonstrating that its TAC-STIM device enhances mood, task performance, and learning among active-duty U.S. Air Force personnel. The findings, presented at the AHFE2025 Conference, indicate the device's effectiveness in high-stress military environments, positioning it as a valuable tool for military and civilian applications. The study builds on previous research, emphasizing TAC-STIM's role in operational readiness and cognitive augmentation.
Read more →ECORelectroCore to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
electroCore, Inc. will participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 20, 2025. The event will be held in New York at The Westin NY Grand Central Hotel, where management will conduct one-on-one meetings with investors. The company focuses on non-invasive bioelectronic technologies to improve health and wellness.
Read more →ECORelectroCore Announces Third Quarter 2025 Financial Results
electroCore, Inc. reported a 33% increase in net sales for Q3 2025, totaling $8.7 million. The company attributed this growth to strong prescription sales, particularly in the Veteran Affairs market. Despite the positive sales performance, electroCore experienced a net loss of $3.4 million, which was higher than the previous year's loss. The company has raised its revenue guidance for the full year 2025.
Read more →ECORelectroCore to Announce Third Quarter September 30, 2025 Financial Results on Wednesday, November 5, 2025
electroCore, Inc. announced it will report its financial results for Q3 2025 on November 5, 2025. The company will host a webinar at 4:30 PM EST to discuss these results and answer investor questions. electroCore specializes in bioelectronic technologies aimed at improving health and wellness.
Read more →ECORelectroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
electroCore, Inc. announced the appointment of Jennifer Hayes as Vice President of Human Resources, effective October 6, 2025. In connection with her employment, the company granted her 10,000 restricted stock units (RSUs) under NASDAQ Listing Rule 5635(c)(4). The RSUs will vest over three years, contingent on her continued employment.
Read more →ECORgammaCore® Non-Invasive Vagus Nerve Stimulation (nVNS) as an Adjunctive Treatment Associated with Improvements in Persistent Post-Concussion Symptoms
electroCore, Inc. announced a peer-reviewed study showing that gammaCore non-invasive vagus nerve stimulation (nVNS) effectively reduces persistent symptoms of mild traumatic brain injury (mTBI). The study found significant improvements in patients treated with nVNS alongside standard care, with benefits observed regardless of the time since injury. No adverse events related to the device were reported.
Read more →ECORelectroCore Announces Reimbursement Approval for gammaCore™ by RIZIV/INAMI in Belgium
electroCore, Inc. announced that its gammaCore Sapphire device has received long-term reimbursement approval from RIZIV/INAMI in Belgium, effective October 1, 2025. This policy will cover treatment for cluster headaches, based on strong clinical evidence. The approval is expected to improve access for patients and reflects the growing recognition of non-invasive therapies.
Read more →ECORelectroCore’s Truvaga™ Plus Named “Best Relaxation Gadget” in Esquire’s 2025 Sleep Awards
electroCore, Inc. announced that its Truvaga Plus device has been awarded 'Best Relaxation Gadget' in Esquire's 2025 Sleep Awards. The recognition highlights the device's effectiveness in reducing stress and promoting better sleep through vagus nerve stimulation. The award is seen as validation for the product's benefits in the wellness market.
Read more →ECORelectroCore Announces Departure of Peter Cuneo from the Board of Directors and Elects Thomas J. Errico, MD as Chairman of the Board
electroCore, Inc. announced the departure of Peter Cuneo from its Board of Directors, with Thomas J. Errico, MD, elected as the new Chairman. Cuneo will remain as a strategic advisor. Errico, a co-founder of the company, is expected to provide valuable leadership and stewardship moving forward.
Read more →ECORelectroCore Partners with iHeartRadio and Former New York Jets Star Linebacker Greg Buttle to Champion Better Sleep and Stress Relief
electroCore has partnered with former NFL linebacker Greg Buttle to promote Truvaga Plus, a handheld vagus nerve stimulation device aimed at enhancing sleep and stress relief. Buttle emphasizes the importance of good sleep for performance, sharing his positive experience with the device. The partnership will include radio and digital campaigns to raise awareness about stress management and wellness.
Read more →Competitive Position
How ECOR ranks across every disease it competes inCompetitive Position is a premium feature
See how ECOR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial